Vilazodone
- Generic Name
- Vilazodone
- Brand Names
- Viibryd
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27N5O2
- CAS Number
- 163521-12-8
- Unique Ingredient Identifier
- S239O2OOV3
- Background
Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors. Vilazodone may also be associated with less sexual dysfunction and weight gain. Vilazodone was given FDA approval on January 21, 2011.
- Indication
用于治疗成人重度抑郁症（MDD）。
- Associated Conditions
- Major Depressive Disorder (MDD)
Eealy Improvement Predicts Antidepressants Response in Adults With Major Depression Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2017-07-26
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT03230682
- Locations
- 🇨🇳
Dept. of Neurology, Huashan Hospital, Fudan University, Shanghai, Shanghai, China
Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
- Conditions
- Bipolar DisorderPregnancy Complications
- Interventions
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Western University, Canada
- Target Recruit Count
- 3357
- Registration Number
- NCT02970721
Early Improvement in Individual Symptoms and Response to Antidepressants in Patients With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 10000
- Registration Number
- NCT02934035
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Conditions
- Bipolar Disorder
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 1037352
- Registration Number
- NCT02893371
- Locations
- 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States
Multimodal Imaging of ECT Effects
- Conditions
- Major Depressive Disorder
- Interventions
- Procedure: electroconvulsive therapy
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 68
- Registration Number
- NCT02871141
- Locations
- 🇩🇪
Charité, Berlin, Germany
Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia
- Conditions
- SchizophreniaSchizoaffective Disorder
- Interventions
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 81921
- Registration Number
- NCT02775864
Can Acupuncture Treat Post-stroke Depression?
- Conditions
- StrokeDepressionStroke Sequelae
- Interventions
- Procedure: Dense cranial electroacupuncture stimulationProcedure: Body acupunctureProcedure: Least acupuncture stimulationOther: Rehabilitation
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 91
- Registration Number
- NCT02644161
- Locations
- 🇭🇰
Department of Rehabilitation, Kowloon Hospital, Kowloon, Hong Kong
🇭🇰Division of Rehabilitation Medicine, Tung Wah Hospital., Sheung Wan, Hong Kong
Predictors of the Outcome of Late Life Depression
- Conditions
- Major Depression
- Interventions
- Other: Treatment as usual (only pharmacological treatment).Other: Psychoeducation
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2018-05-24
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT02441387
- Locations
- 🇧🇷
University of São Paulo, Faculty of Medicine, Institute and Department of Psychiatry, São Paulo, Brazil
A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 330
- Registration Number
- NCT02436239
- Locations
- 🇺🇸
ATP Clinical Research, Costa Mesa, California, United States
🇺🇸Psychiatric Associates, Overland Park, Kansas, United States
🇺🇸Pharmsite Research Inc., Baltimore, Maryland, United States
Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 473
- Registration Number
- NCT02372799
- Locations
- 🇺🇸
Harmonex Neuroscience Research, Dothan, Alabama, United States
🇺🇸Woodland International Research Group, INC, Little Rock, Arkansas, United States
🇺🇸ATP Clinical Research, Costa Mesa, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.